Inaccurate clinical data jeopardizes patient safety and regulatory approval. Our GCP-compliant data management framework ensures data integrity while accelerating submission readiness. ...
Clinical trial delays cost millions and jeopardize patient access. Our GCP-compliant operations eliminate bottlenecks while maintaining uncompromising quality standards across global studies. ...
Developing CGTs is incredibly complex and expensive. Global sponsors face regulatory hurdles, manufacturing complexities, and patient recruitment challenges that can derail even the most promising ...
We're thrilled to announce that Onradivir Tablets (Anruiwei®), supported by our biometrics services, received NMPA approval on May 22, 2025, becoming the world's first influenza RNA ...
